CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $333 | +66.5% | 11,300 | 0.0% | 0.00% | – |
| Q2 2023 | $200 | +13.0% | 11,300 | 0.0% | 0.00% | – |
| Q1 2023 | $177 | -14.1% | 11,300 | 0.0% | 0.00% | -100.0% |
| Q4 2022 | $206 | -99.9% | 11,300 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $214,000 | +8.1% | 11,300 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $198,000 | -7.9% | 11,300 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $215,000 | -22.1% | 11,300 | +9.7% | 0.00% | 0.0% |
| Q4 2021 | $276,000 | +34.6% | 10,300 | +3.0% | 0.00% | 0.0% |
| Q3 2021 | $205,000 | +9.6% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $187,000 | +21.4% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $154,000 | +19.4% | 10,000 | 0.0% | 0.00% | – |
| Q4 2020 | $129,000 | -60.9% | 10,000 | -9.1% | 0.00% | -100.0% |
| Q4 2018 | $330,000 | – | 11,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,030,616 | $31,028,000 | 6.04% |
| 5AM Venture Management, LLC | 1,362,286 | $20,816,000 | 3.75% |
| Burrage Capital Management LLC | 272,393 | $4,162,000 | 3.37% |
| Altium Capital Management LP | 361,930 | $5,530,000 | 1.54% |
| Vivo Capital, LLC | 2,214,138 | $33,832,000 | 1.19% |
| Bain Capital Life Sciences Investors, LLC | 1,071,428 | $16,371,000 | 0.93% |
| Perceptive Advisors | 3,659,381 | $51,606,000 | 0.65% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $2,154,000 | 0.50% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,003,688 | $30,616,000 | 0.45% |
| Opaleye Management Inc. | 188,000 | $2,873,000 | 0.42% |